Live Stock Coverage: Will TherapeuticsMD Inc Go Down Anytime Soon?

Live Stock Coverage: Will TherapeuticsMD Inc Go Down Anytime Soon?

The stock of TherapeuticsMD Inc (NYSEMKT:TXMD) is a huge mover today! About 1.81 million shares traded hands. TherapeuticsMD Inc (NYSEMKT:TXMD) has declined 34.90% since April 4, 2016 and is downtrending. It has underperformed by 35.99% the S&P500.
The move comes after 8 months positive chart setup for the $913.15 million company. It was reported on Nov, 4 by Barchart.com. We have $7.87 PT which if reached, will make NYSEMKT:TXMD worth $465.71M more.

TherapeuticsMD Inc (NYSEMKT:TXMD) Ratings Coverage

Out of 3 analysts covering TherapeuticsMD (NYSEMKT:TXMD), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. TherapeuticsMD has been the topic of 4 analyst reports since September 21, 2015 according to StockzIntelligence Inc. The rating was maintained by Stifel Nicolaus with “Buy” on Tuesday, December 8. Jefferies maintained TherapeuticsMD Inc (NYSEMKT:TXMD) rating on Tuesday, December 8. Jefferies has “Buy” rating and $18.0 price target. The stock of TherapeuticsMD Inc (NYSEMKT:TXMD) has “Buy” rating given on Monday, September 21 by Jefferies.

According to Zacks Investment Research, “TherapeuticsMD, Inc. is a specialty pharmaceutical company focused on creating branded prescription, generic prescription and over-the-counter products targeted exclusively for women. It is developing three advanced hormone replacement products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies. TherapeuticsMD, Inc. is based in Boca Raton, Florida.”

Insitutional Activity: The institutional sentiment decreased to 1.25 in 2016 Q2. Its down 0.78, from 2.03 in 2016Q1. The ratio turned negative, as 19 funds sold all TherapeuticsMD Inc shares owned while 29 reduced positions. 13 funds bought stakes while 47 increased positions. They now own 158.58 million shares or 4.25% more from 152.12 million shares in 2016Q1.
Northern Trust Corp has 1.74M shares for 0% of their US portfolio. Guggenheim Capital Llc holds 0% or 11,513 shares in its portfolio. Fincl Bank Of New York Mellon last reported 0.04% of its portfolio in the stock. Ladenburg Thalmann accumulated 16,325 shares or 0% of the stock. The California-based Menta Cap Ltd Liability Co has invested 0.06% in TherapeuticsMD Inc (NYSEMKT:TXMD). Nicholas Inv Prtn Lp last reported 332,194 shares in the company. Citadel Advsrs Limited Liability Company has 1.08M shares for 0.01% of their US portfolio. Blackrock Inc, a New York-based fund reported 15,223 shares. 1492 Capital Mgmt Ltd Liability Com has 37,488 shares for 0.29% of their US portfolio. Moreover, Heartland Advsrs Inc has 0.29% invested in TherapeuticsMD Inc (NYSEMKT:TXMD) for 600,000 shares. Amer Interest owns 86,402 shares or 0% of their US portfolio. Moreover, Raymond James And Assoc has 0% invested in TherapeuticsMD Inc (NYSEMKT:TXMD) for 181,175 shares. Proshare Llc has invested 0% of its portfolio in TherapeuticsMD Inc (NYSEMKT:TXMD). Commonwealth Equity Ser holds 0% or 17,100 shares in its portfolio. The Minnesota-based Us Retail Bank De has invested 0% in TherapeuticsMD Inc (NYSEMKT:TXMD).

Another recent and important TherapeuticsMD Inc (NYSEMKT:TXMD) news was published by Businesswire.com which published an article titled: “TherapeuticsMD Expands Commercial and Business Development Leadership” on November 03, 2016.

TXMD Company Profile

TherapeuticsMD, Inc., incorporated on July 20, 2010, is a women’s healthcare product company. The Company’s segment is creating and commercializing products for women. The Firm is focused on conducting clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy pharmaceutical products. The Company’s drug candidates used in its clinical trials are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort. The Company’s drug candidates are created using its SYMBODA hormone technology, which enables the administration of hormones with high bioavailability alone or in combination. The Firm makes and distributes branded and generic prescription prenatal vitamins, as well as over-the-counter (OTC) vitamins.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment